Truist lowered the firm’s price target on Pennant Group (PNTG) to $28 from $32 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm’s coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group acquires GrandCare Health Services
- Wells says CMS proposed rates worse than expected, final rate likely to improve
- Home health stocks under pressure following proposed rate cuts
- Pennant Group price target raised to $31 from $30 at Wells Fargo
- Pennant Group Holds Annual Stockholders Meeting